Assessing social risks prior to commencement of a clinical trial: due diligence or ethical inflation?

Scott Burris, Corey Davis

Research output: Contribution to journalArticle

Abstract

Assessing social risks has proven difficult for IRBs. We undertook a novel effort to empirically investigate social risks before an HIV prevention trial among drug users in Thailand and China. The assessment investigated whether law, policies and enforcement strategies would place research subjects at significantly elevated risk of arrest, incarceration, physical harm, breach of confidentiality, or loss of access to health care relative to drug users not participating in the research. The study validated the investigator's concern that drug users were subject to serious social risks in the site localities, but also suggested that participation in research posed little or no marginal increase in risk and might even have a protective effect. Our experience shows that it is feasible to inform IRB deliberations with actual data on social risks, but also raises the question of whether and when such research is an appropriate use of scare research resources.

Original languageEnglish (US)
Pages (from-to)48-54
Number of pages7
JournalAmerican Journal of Bioethics
Volume9
Issue number11
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Economic Inflation
Clinical Trials
Drug Users
Research Ethics Committees
Research
Research Subjects
Law Enforcement
Health Services Accessibility
Confidentiality
Thailand
China
Research Personnel
HIV

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Assessing social risks prior to commencement of a clinical trial : due diligence or ethical inflation? / Burris, Scott; Davis, Corey.

In: American Journal of Bioethics, Vol. 9, No. 11, 11.2009, p. 48-54.

Research output: Contribution to journalArticle

@article{7d7132d1f6324b3f81caf3d57268f06f,
title = "Assessing social risks prior to commencement of a clinical trial: due diligence or ethical inflation?",
abstract = "Assessing social risks has proven difficult for IRBs. We undertook a novel effort to empirically investigate social risks before an HIV prevention trial among drug users in Thailand and China. The assessment investigated whether law, policies and enforcement strategies would place research subjects at significantly elevated risk of arrest, incarceration, physical harm, breach of confidentiality, or loss of access to health care relative to drug users not participating in the research. The study validated the investigator's concern that drug users were subject to serious social risks in the site localities, but also suggested that participation in research posed little or no marginal increase in risk and might even have a protective effect. Our experience shows that it is feasible to inform IRB deliberations with actual data on social risks, but also raises the question of whether and when such research is an appropriate use of scare research resources.",
author = "Scott Burris and Corey Davis",
year = "2009",
month = "11",
language = "English (US)",
volume = "9",
pages = "48--54",
journal = "American Journal of Bioethics",
issn = "1526-5161",
publisher = "Routledge",
number = "11",

}

TY - JOUR

T1 - Assessing social risks prior to commencement of a clinical trial

T2 - due diligence or ethical inflation?

AU - Burris, Scott

AU - Davis, Corey

PY - 2009/11

Y1 - 2009/11

N2 - Assessing social risks has proven difficult for IRBs. We undertook a novel effort to empirically investigate social risks before an HIV prevention trial among drug users in Thailand and China. The assessment investigated whether law, policies and enforcement strategies would place research subjects at significantly elevated risk of arrest, incarceration, physical harm, breach of confidentiality, or loss of access to health care relative to drug users not participating in the research. The study validated the investigator's concern that drug users were subject to serious social risks in the site localities, but also suggested that participation in research posed little or no marginal increase in risk and might even have a protective effect. Our experience shows that it is feasible to inform IRB deliberations with actual data on social risks, but also raises the question of whether and when such research is an appropriate use of scare research resources.

AB - Assessing social risks has proven difficult for IRBs. We undertook a novel effort to empirically investigate social risks before an HIV prevention trial among drug users in Thailand and China. The assessment investigated whether law, policies and enforcement strategies would place research subjects at significantly elevated risk of arrest, incarceration, physical harm, breach of confidentiality, or loss of access to health care relative to drug users not participating in the research. The study validated the investigator's concern that drug users were subject to serious social risks in the site localities, but also suggested that participation in research posed little or no marginal increase in risk and might even have a protective effect. Our experience shows that it is feasible to inform IRB deliberations with actual data on social risks, but also raises the question of whether and when such research is an appropriate use of scare research resources.

UR - http://www.scopus.com/inward/record.url?scp=73349142729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349142729&partnerID=8YFLogxK

M3 - Article

C2 - 19882460

AN - SCOPUS:73349142729

VL - 9

SP - 48

EP - 54

JO - American Journal of Bioethics

JF - American Journal of Bioethics

SN - 1526-5161

IS - 11

ER -